1. Scrip
  2. >>New Products

Imfinzi Adds Approval In Early-Stage Lung Cancer, Matching Keytruda

 
• By Joseph Haas

AstraZeneca is working to bolster its PD-L1 agent’s applicability in resectable non-small cell lung cancer, seeking advantages versus Merck’s Keytruda and Bristol’s Opdivo.

AZN
AstraZeneca adds early-stage lung cancer perioperative indication to Imfinzi's label • Source: Shutterstock

Despite a complicated advisory committee review in July, AstraZeneca PLC obtained supplemental US Food and Drug Administration approval on 16 August for its PD-L1 inhibitor Imfinzi for perioperative treatment in resectable non-small cell lung cancer (NSCLC) meeting certain requirements, putting its drug on an equal footing in that setting with Merck & Co., Inc.'s Keytruda and ahead of Bristol Myers Squibb Company’s Opdivo.

Key Takeaways

  • AstraZeneca received FDA approval for perioperative therapy with Imfinzi in early-stage resectable lung cancer, despite advisory panel reservations about clinical benefit.

The indication clears Imfinzi (durvalumab) for use prior to surgery, in tandem with platinum-based chemotherapy, in early-stage NSCLC tumors no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.